COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Acquires California Skilled Nursing Facility
05/03/2019
MISSION VIEJO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care [...]
CampDoc Launches Discounted Epinephrine Auto-Injector Pricing Program for Camps
05/03/2019
ANN ARBOR, Mich., March 05, 2019 (GLOBE NEWSWIRE) -- CampDoc, the leading electronic health record system for camps, announced the launch of CampEpi, a new program offering discounted epinephrine auto-injector pricing [...]
PDMR Dealing
05/03/2019
LONDON, March 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Transactions in relation to share buyback program
05/03/2019
Transactions in relation to share buyback program Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the [...]
DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors
05/03/2019
Montrouge, France, March 5, 2019 DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors Mr. de Rosen to succeed DBV’s co-founder, Dr. Pierre-Henri Benhamou, who [...]
DBV Technologies annonce la nomination de Michel de Rosen en tant que Président non-exécutif du conseil d'administration
05/03/2019
Montrouge, France, 5 mars (7 h 30 CET) 2019 DBV Technologies annonce la nomination de Michel de Rosen en tant que Président non-exécutif du conseil d'administration Michel de Rosen succède au co-fondateur de DBV, le Dr [...]
Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
05/03/2019
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara [...]
MDxHealth : SelectMDx® Liquid Biopsy Test for Prostate Cancer Included in the 2019 Italian Society of Urology Guidelines
05/03/2019
NEWS RELEASE MDxHealth's SelectMDx ® Liquid Biopsy Test for Prostate Cancer Included in the 2019 Italian Society of Urology Guidelines A significant milestone to increase adoption of SelectMDx in Italy IRVINE, CA, and [...]
Darolutamide submitted for marketing authorization in Japan
05/03/2019
Orion Corporation Press release 5 March 2019 at 8.00 a.m. EET Darolutamide submitted for marketing authorization in Japan Regulatory submission based on positive data from the Phase III ARAMIS trial Orion Corporation [...]
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
05/03/2019
Major 2018 Accomplishments Driven by Positive Clinical Trial Results - Significant increase in rates of pregnancy and live birth (up to 35% increase in Day 5 ET) in Phase 3 IMPLANT 2 trial of nolasiban in IVF procedures [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
05/03/2019
Regulated information Gosselies, Belgium, 5 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
05/03/2019
Information réglementée Gosselies, Belgique, le 5 mars 2019, 07h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins médicaux [...]
Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares
05/03/2019
BOTHELL, Wash., March 04, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced [...]
MULTIMEDIA UPDATE - AHIMA Joins with Artifact Health, Provides Standardized, Compliant Templates For Platform that Streamlines Time-Consuming Physician Queries
05/03/2019
CHICAGO and BOULDER, Colo., March 04, 2019 (GLOBE NEWSWIRE) -- The American Health Information Management Association (AHIMA) has joined with Artifact Health to provide and maintain a comprehensive library of compliant [...]
aTyr Pharma Announces Participation at March Investor Conferences
04/03/2019
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Psychemedics Corporation Announces 3rd Straight Year of Record Revenue; Declares 90th Consecutive Quarterly Dividend
04/03/2019
ACTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2018. The Company also announced a [...]
Kezar Life Sciences Strengthens Management Team, Appoints Celia Economides as Senior Vice President, Strategy and External Affairs
04/03/2019
SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet [...]
Sientra® to Release Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
04/03/2019
SANTA BARBARA, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its fourth quarter and full [...]
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018
04/03/2019
EMERYVILLE, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2018, [...]

Pages